Morten Haugen/LinkedIn
Sep 19, 2025, 16:48
Morten Haugen Warns of IgG Risks for High-Frequency Plasma Donors
Morten Haugen, Resident physician specializing in immunology and transfusion medicine at Oslo University Hospital, shared a post on LinkedIn:
“New evidence on plasma donation frequency:
- The first paper from my PhD-work is now published in Vox Sanguinis! In this randomized trial we found that
High-frequency (3×/2 weeks) and regular-frequency (1×/2 weeks) plasma donation significantly lowered total serum protein and immunoglobulin G. - Up to 26% of high-frequency donors dropped below the IgG safety threshold of 6.0 g/L, even when starting with normal levels of more than 8.0 g/L in most donors.
- Many plasma proteins had not recovered 4 weeks after the last donation.
These findings highlight the need for careful donor monitoring and further research into long-term health effects.
Full article here

Thanks to the volunteer blood donors, the research team and my co-authors Karin Magnussen, Tor Strand and Lise Sofie Nissen-Meyer for making the study possible.”
Stay updated with Hemostasis Today.
-
Jan 12, 2026, 14:46A Behcet Disease with Aortic Thrombosis: Alexandru Stieber Shares A Peculiar Case
-
Jan 12, 2026, 04:51Coronary Microvascular Dysfunction and HFpEF․ Prognostic Importance and Therapeutic Insights
-
Jan 12, 2026, 04:16Wolfgang Miesbach on VTE and Cancer: A 20-Year Signal That Can’t Be Ignored
-
Jan 12, 2026, 03:54Francine Freitas Fernandes on Transvaginal US for Pelvic Venous Disorders
-
Jan 12, 2026, 02:58Jara Garcia Ugaldebere Shares STORM-PE Results: Thrombectomy Plus Anticoagulation for Acute High-Risk PE
-
Jan 12, 2026, 02:54Discover the New Blood Project․ Enhanced Search, Browsing, and Learning Resources
-
Jan 12, 2026, 02:54Can Preoperative Iron Status Predict Severe Anemia After Bariatric Surgery?
-
Jan 12, 2026, 02:27Bryce Kerlin to Impact of Advanced Hemostasis/Thrombosis Fellowship Training at Haemophilia Publication
-
Jan 12, 2026, 02:21Martin Haluzík on Compariosn of Cardiovascular Outcomes Between Semaglutide and Dulaglutide Therapies
